Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System
Bio-Techne (NASDAQ: TECH) has announced the release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, aimed at supporting immune cell- and stem cell-based therapy development and manufacturing. The system offers significant advantages over traditional lentivirus-based engineering methods, featuring a hyperactive enzyme capable of delivering multiple genes simultaneously while maintaining high editing efficiency.
The TcBuster system eliminates the need for viral clearance methods, reducing time to market and costs for cell therapy developers. It's compatible with various cell types, including immune cells and stem cells, and can be used for applications like autologous CAR-T, TCR manufacturing, allogeneic NK therapies, and engineering bioprocessing cell lines. Bio-Techne provides both RUO & GMP grade reagents with closed-system manufacturing options.
Bio-Techne (NASDAQ: TECH) ha annunciato il rilascio di mRNA GMP Transposase per il sistema di ingegneria genomica non virale TcBuster™, progettato per supportare lo sviluppo e la produzione di terapie basate su cellule immunitarie e staminali. Il sistema offre vantaggi significativi rispetto ai metodi tradizionali di ingegneria basati su lentivirus, presentando un enzima iperattivo capace di consegnare più geni simultaneamente mantenendo un'alta efficienza di editing.
Il sistema TcBuster elimina la necessità di metodi di rimozione virale, riducendo i tempi di immissione sul mercato e i costi per gli sviluppatori di terapie cellulari. È compatibile con vari tipi di cellule, incluse le cellule immunitarie e le cellule staminali, e può essere utilizzato per applicazioni come CAR-T autologo, produzione di TCR, terapie NK allogeniche e ingegnerizzazione di linee cellulari per bioprocessi. Bio-Techne fornisce sia reagenti di grado RUO che GMP con opzioni di produzione in sistema chiuso.
Bio-Techne (NASDAQ: TECH) ha anunciado el lanzamiento de GMP Transposase mRNA para el sistema de ingeniería genómica no viral TcBuster™, destinado a apoyar el desarrollo y la fabricación de terapias basadas en células inmunitarias y células madre. El sistema ofrece ventajas significativas sobre los métodos tradicionales de ingeniería basados en lentivirus, presentando una enzima hiperactiva capaz de entregar múltiples genes simultáneamente mientras mantiene una alta eficiencia de edición.
El sistema TcBuster elimina la necesidad de métodos de limpieza viral, reduciendo el tiempo de comercialización y los costos para los desarrolladores de terapias celulares. Es compatible con varios tipos de células, incluidas las células inmunitarias y las células madre, y se puede utilizar para aplicaciones como CAR-T autólogo, fabricación de TCR, terapias NK alogénicas y la ingeniería de líneas celulares de bioprocesamiento. Bio-Techne proporciona reactivos de grado RUO y GMP con opciones de fabricación en sistema cerrado.
Bio-Techne (NASDAQ: TECH)는 TcBuster™ 비바이러스 유전자 공학 시스템을 위한 GMP 전이효소 mRNA의 출시를 발표했습니다. 이 시스템은 면역 세포 및 줄기 세포 기반 치료 개발 및 제조를 지원하기 위해 설계되었습니다. 이 시스템은 전통적인 렌티바이러스 기반 공학 방법에 비해 상당한 이점을 제공하며, 여러 유전자를 동시에 전달할 수 있는 하이퍼 액티브 효소를 특징으로 하여 높은 편집 효율을 유지합니다.
TcBuster 시스템은 바이러스 제거 방법의 필요성을 없애주며, 세포 치료 개발자의 시장 진입 시간과 비용을 줄여줍니다. 면역 세포와 줄기 세포를 포함한 다양한 세포 유형과 호환되며, 자가 CAR-T, TCR 제조, 동종 NK 치료 및 생물 공정 세포주 공학과 같은 응용 프로그램에 사용할 수 있습니다. Bio-Techne는 폐쇄형 시스템 제조 옵션과 함께 RUO 및 GMP 등급의 시약을 제공합니다.
Bio-Techne (NASDAQ: TECH) a annoncé le lancement de l'ARNm GMP Transposase pour le système d'ingénierie génomique non viral TcBuster™, destiné à soutenir le développement et la fabrication de thérapies basées sur des cellules immunitaires et des cellules souches. Le système offre des avantages significatifs par rapport aux méthodes d'ingénierie traditionnelles basées sur des lentivirus, avec une enzyme hyperactive capable de livrer plusieurs gènes simultanément tout en maintenant une haute efficacité d'édition.
Le système TcBuster élimine le besoin de méthodes de purification virale, réduisant ainsi le temps de mise sur le marché et les coûts pour les développeurs de thérapies cellulaires. Il est compatible avec divers types de cellules, y compris les cellules immunitaires et les cellules souches, et peut être utilisé pour des applications telles que CAR-T autologue, fabrication de TCR, thérapies NK allogéniques et ingénierie de lignées cellulaires de bioprocessing. Bio-Techne fournit des réactifs de grade RUO et GMP avec des options de fabrication en système fermé.
Bio-Techne (NASDAQ: TECH) hat die Veröffentlichung von GMP Transposase mRNA für das TcBuster™ nicht-virale Genom-Engineering-System angekündigt, das darauf abzielt, die Entwicklung und Herstellung von Therapien auf Basis von Immunzellen und Stammzellen zu unterstützen. Das System bietet erhebliche Vorteile gegenüber traditionellen lentivirus-basierten Engineering-Methoden und verfügt über ein hyperaktives Enzym, das in der Lage ist, mehrere Gene gleichzeitig zu liefern und dabei eine hohe Editierungseffizienz aufrechtzuerhalten.
Das TcBuster-System beseitigt die Notwendigkeit von viralen Reinigungstechniken, wodurch die Markteinführungszeit und die Kosten für Entwickler von Zelltherapien gesenkt werden. Es ist mit verschiedenen Zelltypen, einschließlich Immunzellen und Stammzellen, kompatibel und kann für Anwendungen wie autologe CAR-T, TCR-Herstellung, allogene NK-Therapien und die Ingenieurierung von Bioprozesszelllinien verwendet werden. Bio-Techne bietet sowohl RUO- als auch GMP-Grad-Reagenzien mit geschlossenen Herstellungsoptionen an.
- Introduction of new GMP product expanding market opportunities in cell therapy development
- Technology offers cost and time reduction benefits compared to traditional methods
- Product features enhanced efficiency through hyperactive enzyme capabilities
- Strong and reliable supply chain for both RUO & GMP grade reagents
- None.
Insights
The release of the GMP-certified TcBuster system marks a pivotal advancement in Bio-Techne's cell therapy manufacturing portfolio, with significant commercial implications. The GMP certification is particularly important as it enables immediate clinical applications, potentially accelerating Bio-Techne's penetration into the rapidly growing cell therapy market, projected to reach
The system's key technological advantages create compelling value propositions: The hyperactive enzyme design enables simultaneous multi-gene delivery while maintaining high editing efficiency - a critical feature for next-generation cell therapies. By eliminating viral clearance requirements, the system can potentially reduce manufacturing timelines by
From a competitive standpoint, Bio-Techne's established supply chain for both Research Use Only (RUO) and GMP grade reagents provides a significant advantage. The company's ability to offer closed-system manufacturing solutions positions it as a one-stop shop for cell therapy developers, from initial research through commercial production. This integrated approach could drive substantial recurring revenue streams as clients scale from development to commercial manufacturing.
The broad compatibility with various cell types, including immune cells and stem cells, expands the addressable market beyond traditional CAR-T applications to include emerging therapeutic areas such as NK cell therapies and engineered cell lines for biologics production. This diversification reduces market risk while maximizing revenue potential across multiple therapeutic modalities.
The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types. The new GMP transposase will offer a clearer path to clinic for applications in gene edited cell therapies, such as CAR-T or TCR generation.
Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods for cell therapy development. The natural transposase has been enhanced through protein engineering, resulting in a hyperactive enzyme. As a result, multiple genes can be delivered from a GMP transposon simultaneously while maintaining high editing efficiency and a de-risked insertional profile. By negating the need for viral clearance methods, the TcBuster system also significantly reduces both the time to market and cost requirements for cell therapy developers. Moreover, Bio-Techne has a strong and reliable supply chain for both RUO & GMP grade reagents, including innovative options for closed-system manufacturing, making it a dependable option for scaling from research to clinical and commercial stages.
"Our customers rely on us to help de-risk their cell therapy manufacturing programs and support their scale up to clinical trials and commercial manufacturing," said Will Geist, President Bio-Techne's Protein Science Segment. "Releasing a GMP version of our TcBuster non-viral genome engineering system marks a significant advance in meeting that goal, providing cell therapy developers with a powerful tool for efficient gene editing without the drawbacks of traditional viral delivery systems."
The TcBuster system is compatible with a range of cell types, including immune cells and stem cells, and can be used for a wide range of applications, including autologous CAR-T or TCR manufacturing, allogeneic NK therapies, and for engineering bioprocessing cell lines for therapeutic biologics production.
The GMP TcBuster transposase is available now online at www.bio-techne.com/tcbuster. For more information on the TcBuster non-viral genome engineering system, please visit our website or contact us directly.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-release-of-gmp-tcbuster-non-viral-genome-engineering-system-302376063.html
SOURCE Bio-Techne Corporation
FAQ
What is Bio-Techne's new GMP TcBuster system and how does it impact cell therapy development?
How does TECH's TcBuster system differ from traditional lentivirus-based engineering methods?
What cell types are compatible with Bio-Techne's TcBuster system?
What are the key advantages of TECH's GMP TcBuster for cell therapy manufacturers?
